Teva Pharmaceuticals U
Trial Pipeline
Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
NCT04976192
Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions
NCT01340625
Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions
NCT00974012
Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions
NCT01182207
10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.
NCT01260922
Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions
NCT00830024
Valacyclovir 1000 mg Tablet Under Fasting Conditions
NCT01149499
Cefadroxil 500 mg Capsules Under Fasting Conditions
NCT00834275
Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.
NCT00835081
Lansoprazole 30 mg DR Capsule Fasting Study
NCT01045967
Cefprozil for Oral Suspension 250 mg/5 mL, Fasting
NCT00835614
Cilostazol 50 mg Tablets Under Fasting Conditions
NCT00839930
Cilostazol 100 mg Tablet Formulations Under Fasting Conditions
NCT00838630
Azithromycin 600 Mg Tablets, Fasting
NCT00834756
Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions
NCT00840411
Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.
NCT00840216
Azithromycin 600 Mg Tablets, Fed
NCT00834132
Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
NCT00835276
Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions
NCT00833664
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for Teva Pharmaceuticals U Shows
According to the ClinicalTrials.gov registry, Teva Pharmaceuticals U is linked to 19 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 19 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Teva Pharmaceuticals U reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 18 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Teva Pharmaceuticals U is Healthy with 17 linked trials, and 2 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.